Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report) and keeping the price target at $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
William Plovanic has given his Buy rating due to a combination of factors including strategic leadership changes and promising market developments. The appointment of David Patience as the new CFO, despite the less than ideal timing, is seen as a positive move. Mr. Patience’s extensive background in finance and corporate development is expected to enhance the company’s strategic direction.
Additionally, the recent introduction of a HCPCS code for mapping procedures and the full market launch of the TriNav LV device are significant catalysts. These developments are anticipated to expand the company’s market reach and contribute to substantial revenue growth. Plovanic is confident that TriSalus Life Sciences is well-positioned to achieve or surpass its financial targets, which justifies the Buy rating.
According to TipRanks, Plovanic is a 4-star analyst with an average return of 4.0% and a 46.30% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, TriSalus Life Sciences, and Atricure.
In another report released on May 30, Lake Street also reiterated a Buy rating on the stock with a $10.00 price target.